Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

AstraZeneca commences phase II monotherapy trials of ZD-0473

Dec. 21, 1999

Discovery of potent FTase inhibitors with excellent cellular and in vivo activity reported by Abbott

Dec. 21, 1999

Oxford Asymmetry achieves first milestone in collaboration with Ontogeny

Dec. 21, 1999

Phase I clinical trial initiated with OSI's second anticancer agent

Dec. 20, 1999

Genentech's rhuMAb-VEGF will move to phase III study

Dec. 20, 1999

ImClone Systems files IND in U.S. for antiangiogenic agent

Dec. 20, 1999

BMS and Oxigene establish agreement for combretastatin antitumor agents

Dec. 17, 1999

Targeted Genetics commences phase I trial of tgDCC-E1A for ovarian cancer

Dec. 17, 1999

Schwarz to develop Cephalon's prostate cancer drugs in Europe

Dec. 17, 1999

AEterna and the NCI file IND for Neovastat in North America

Dec. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...